Scintigraphic biomarkers for colonic dysmotility

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 748-753

  Camilleri, M ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALOSETRON; ASIMADOLINE; BIOLOGICAL MARKER; BISACODYL; DEXLOXIGLUMIDE; INDIUM 111; LINACLOTIDE; LUBIPROSTONE; METHACRYLIC ACID; NEUROTROPHIN; PEXACERFONT; PRUCALOPRIDE; SEROTONIN 4 AGONIST; SOLABEGRON; TECHNETIUM 99M; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG;

CHRONIC DIARRHEA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISSOLUTION; DRUG STABILITY; HUMAN; INTESTINAL DYSMOTILITY; INTESTINE FUNCTION; INTESTINE TRANSIT TIME; IRRITABLE COLON; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SCINTILLATION CAMERA;

BIOLOGICAL MARKERS; COLONIC DISEASES; DRUG APPROVAL; DRUG DESIGN; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; INDIVIDUALIZED MEDICINE; RADIONUCLIDE IMAGING; REPRODUCIBILITY OF RESULTS;

EID: 77952581741     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.23     Document Type: Review

References (37)

1. Biomarkers Defnitions Working Group. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
2. Wagner, J.A. Biomarkers: principles, policies, and practice. Clin. Pharmacol. Ther. 86, 3-7 (2009).
3. Lathia, C.D. et al. The value, qualifcation, and regulatory use of surrogate end points in drug development. Clin. Pharmacol. Ther. 86, 32-43 (2009).
4. Spiller, R.C., Brown, M.L. & Phillips, S.F. Emptying of the terminal ileum in intact humans. Infuence of meal residue and ileal motility. Gastroenterology 92, 724-729 (1987).
5. von der Ohe, M.R., Camilleri, M., Kvols, L.K. & Thomforde, G.M. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N. Engl. J. Med. 329, 1073-1078 (1993).
6. Camilleri, M. et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 6, 772-781 (2008).
7. Manabe, N., Wong, B.S., Camilleri, M., Burton, D., McKinzie, S. & Zinsmeister, A.R. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol. Motil. (2009); e-pub ahead of print 21 December 2009.
8. Cremonini, F., Mullan, B.P., Camilleri, M., Burton, D.D. & Rank, M.R. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment. Pharmacol. Ther. 16, 1781-1790 (2002).
9. Deiteren, A. et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol. Motil. (2009); e-pub ahead of print 18 December 2009.
10. Andresen, V., Montori, V.M., Keller, J., West, C.P., Layer, P. & Camilleri, M. Efects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin. Gastroenterol. Hepatol. 6, 545-555 (2008).
11. Prather, C.M., Camilleri, M., Zinsmeister, A.R., McKinzie, S. & Thomforde, G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118, 463-468 (2000). (Pubitemid 30140843)
12. Bouras, E.P., Camilleri, M., Burton, D.D., Thomforde, G., McKinzie, S. & Zinsmeister, A.R. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120, 354-360 (2001).
13. Camilleri, M., Kerstens, R., Rykx, A. & Vandeplassche, L. A randomized, placebo-controlled trial to evaluate the efcacy, safety and efect on quality of life of prucalopride in severe chronic constipation. N. Engl. J. Med. 358, 2344-2354 (2008).
14. Manini, M.L. et al. Efects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol. Motil. 22, 42-9, e7 (2010).
15. Goldberg, M.R., Li, Y.-P., Pitzer, K., Johanson, J.F., Mangel, A.W., & Kitt, M.M. T1389 TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response defnition in patients with chronic constipation. Gastroenterology 134, A545 (2008).
16. Manabe, N., Cremonini, F., Camilleri, M., Sandborn, W.J. & Burton, D.D. Efects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment. Pharmacol. Ther. 30, 930-936 (2009).
17. Kienzle-Horn, S., Vix, J.M., Schuijt, C., Peil, H., Jordan, C.C. & Kamm, M.A. Efcacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment. Pharmacol. Ther. 23, 1479-1488 (2006).
18. Coulie, B. et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119, 41-50 (2000).
19. Parkman, H.P. et al.; Functional Constipation Study Investigators. Neurotrophin-3 improves functional constipation. Am. J. Gastroenterol. 98, 1338-1347 (2003).
20. Camilleri, M. et al. Efect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G942-G947 (2006).
21. Johanson, J.F., Morton, D., Geenen, J. & Ueno, R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol. 103, 170-177 (2008).
22. Johanson, J.F. & Ueno, R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efcacy and safety. Aliment. Pharmacol. Ther. 25, 1351-1361 (2007).
23. Johanson, J.F., Drossman, D.A., Panas, R., Wahle, A. & Ueno, R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 27, 685-696 (2008).
24. Drossman, D.A., Chey, W., Panas, R., Wahle, A., Scott, C. & Ueno, R. Lubiprostone signifcantly improves symptom relief rates in adults with IBS. Gastroenterology 132, 2586-2587 (2007).
25. Andresen, V. et al. Efect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133, 761-768 (2007).
26. Johnston, J.M. et al. Pilot study on the efect of linaclotide in patients with chronic constipation. Am. J. Gastroenterol. 104, 125-132 (2009).
27. Delvaux, M., Beck, A., Jacob, J., Bouzamondo, H., Weber, F.T. & Frexinos, J. Efect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 20, 237-246 (2004).
28. Szarka, L.A. et al. Efcacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 5, 1268-1275 (2007).
29. Mangel, A.W. et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 28, 239-249 (2008).
30. Cremonini, F. et al. Efect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am. J. Gastroenterol. 100, 652-663 (2005).
31. D'Amato, M., Whorwell, P.J. & Thompson, D.G. The efcacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut 45 (suppl. 5), A258 (1999).
32. Whorwell, P.J. et al. A phase III, 6-month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK-1 antagonist dexloxiglumide in constipation-predominant IBS: the Darwin study. Gastroenterology 134, A157 (2008).
33. Sweetser, S. et al. Do corticotropin releasing factor-1 receptors infuence colonic transit and bowel function in women with irritable bowel syndrome? Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1299-G1306 (2009).
34. Duke, G.E., Mayer, E.A., Kelleher, D.L., Hicks, K.J., Boardley, R.L. & Alpers, D.H. A randomised, double blind, placebo (PLA) controlled, crossover study to evaluate the efcacy and safety of the corticotrophin releasing factor 1 (CRF1) receptor antagonist (RA) GW876008 in irritable bowel syndrome (IBS) patients. Neurogastroenterol. Motil. 21 (suppl.), 84 (abstract, 2009).
35. Grudell, A.B. et al. Dose-response efect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1114-G1119 (2008).
36. Kelleher, D.L., Hicks, K.J., Cox, D.S., Williamson, R.R., Alpers, D.H. & Dukes, G.E. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efcacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol. Motil. 20 (suppl. 1), 131-132 (abstract, 2008).
37. Camilleri, M. et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123, 425-432 (2002).